Cardiaccs AS is thrilled to announce the successful raise of 4,900,000, marking a pivotal milestone in the company’s journey to revolutionize cardiac care through continuous heart monitoring. Established in 2009 after eight years of intensive research and development, Cardiaccs has emerged as a trusted innovator in the field of cardiac surgery and post-operative care. The company’s groundbreaking technology offers real-time, continuous monitoring of heart function during and after cardiac procedures, ultimately promising to enhance patient outcomes and reduce post-operative complications through timely interventions. Since February 2016, Cardiaccs has been ISO 13485 certified, a testament to its rigorous commitment to quality and excellence in the design and development of medical devices.
The recently raised funds will be strategically utilized to scale up research and development initiatives, accelerate product enhancements, and broaden clinical trials that validate the efficacy of this vital monitoring technology. Additionally, part of the investment will support regulatory approvals and market expansion efforts, ensuring that this state-of-the-art monitoring system reaches healthcare institutions worldwide. With this financial boost, Cardiaccs is well-positioned to fortify its leadership in the medical device industry and continue pushing the boundaries of innovation in cardiac care. This latest round of funding not only underscores investor confidence in Cardiaccs’ vision and technological prowess but also paves the way for improved patient safety and quality of care on a global scale.
